Incorporation of Prognostic and Predictive Factors into Glioma Clinical Trials

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2012 Nov 6

PMID 23125011

Citations 16

Authors

Derek R Johnson

Evanthia Galanis

Affiliations

Soon will be listed here.

Abstract

Treatment of brain tumors is increasingly informed by biomarkers that predict patient prognosis and response to therapy. While this progress represents a great opportunity for the field of neuro-oncology, it also presents significant challenges. Biomarkers are not straightforward to identify, and previously used clinical trial paradigms are poorly suited to the task of identifying treatments effective only in selected subsets of patients. Unless investigators adapt new tools and procedures that better account for the biological diversity of gliomas, future clinical trials run the dual risk of missing important treatment effects and exposing patients to interventions destined to prove ineffective for their tumors. In this article, we will review the progress made in the past decade with respect to biomarkers in neuro-oncology, address barriers to ongoing progress, and discuss clinical trial designs that may prove useful in moving neuro-oncology fully into the era of personalized medicine.

Citing Articles

Examining the Landscape of Prognostic Factors and Clinical Outcomes for Cancer Control.

Giuliani M, Giannopoulos E, Gospodarowicz M, Broadhurst M, OSullivan B, Tittenbrun Z Curr Oncol. 2021; 28(6):5155-5166.

PMID: 34940071 PMC: 8699872. DOI: 10.3390/curroncol28060432.

Microrchidia family CW‑type zinc finger 2 promotes the proliferation, invasion, migration and epithelial‑mesenchymal transition of glioma by regulating PTEN/PI3K/AKT signaling via binding to N‑myc downstream regulated gene 1 promoter.

Zhang J, Yang Y, Dong Y, Liu C Int J Mol Med. 2021; 49(2).

PMID: 34913078 PMC: 8711590. DOI: 10.3892/ijmm.2021.5071.

Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide.

Lo Dico A, Martelli C, Diceglie C, Lucignani G, Ottobrini L Front Oncol. 2018; 8:249.

PMID: 30013951 PMC: 6036118. DOI: 10.3389/fonc.2018.00249.

Clinical relevance of lysyl oxidase-like 2 and functional mechanisms in glioma.

Du X, Zhu M Onco Targets Ther. 2018; 11:2699-2708.

PMID: 29785119 PMC: 5953268. DOI: 10.2147/OTT.S164056.

miRNA‑1271 inhibits cell proliferation in neuroglioma by targeting fibronectin 1.

Gong J, Wang Z, Liu Z Mol Med Rep. 2017; 16(1):143-150.

PMID: 28535003 PMC: 5482146. DOI: 10.3892/mmr.2017.6610.

References

Desestret V, Ciccarino P, Ducray F, Criniere E, Boisselier B, Labussiere M . Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol. 2011; 105(2):219-24. DOI: 10.1007/s11060-011-0587-4. View

Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D . Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006; 24(18):2707-14. DOI: 10.1200/JCO.2005.04.3414. View

Sargent D, Conley B, Allegra C, Collette L . Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005; 23(9):2020-7. DOI: 10.1200/JCO.2005.01.112. View

Baker S, Sargent D . Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. J Natl Cancer Inst. 2010; 102(23):1756-9. PMC: 2994862. DOI: 10.1093/jnci/djq427. View

Song X, Zhou X . Evaluating markers for treatment selection based on survival time. Stat Med. 2011; 30(18):2251-64. DOI: 10.1002/sim.4258. View

Olar A, Raghunathan A, Albarracin C, Aldape K, Cahill 3rd D, Powell S . Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Ann Diagn Pathol. 2011; 16(3):161-70. DOI: 10.1016/j.anndiagpath.2011.08.010. View

Sampson J, Archer G, Mitchell D, Heimberger A, Herndon 2nd J, Lally-Goss D . An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009; 8(10):2773-9. PMC: 2991139. DOI: 10.1158/1535-7163.MCT-09-0124. View

Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussiere M, Lesimple T . Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of.... Cancer. 2012; 118(17):4201-11. DOI: 10.1002/cncr.27392. View

Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen P . Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012; 13(5):e196-204. DOI: 10.1016/S1470-2045(11)70406-5. View

10.

Barker A, Sigman C, Kelloff G, Hylton N, Berry D, Esserman L . I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009; 86(1):97-100. DOI: 10.1038/clpt.2009.68. View

11.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. DOI: 10.1093/jnci/dji237. View

12.

Hamburg M, Collins F . The path to personalized medicine. N Engl J Med. 2010; 363(4):301-4. DOI: 10.1056/NEJMp1006304. View

13.

Cai T, Tian L, Wong P, Wei L . Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics. 2010; 12(2):270-82. PMC: 3062150. DOI: 10.1093/biostatistics/kxq060. View

14.

Freidlin B, McShane L, Korn E . Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010; 102(3):152-60. PMC: 2911042. DOI: 10.1093/jnci/djp477. View

15.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

16.

Baker S, Kramer B, Sargent D, Bonetti M . Biomarkers, subgroup evaluation, and clinical trial design. Discov Med. 2012; 13(70):187-92. View

17.

Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

18.

Malmstrom A, Gronberg B, Marosi C, Stupp R, Frappaz D, Schultz H . Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13(9):916-26. DOI: 10.1016/S1470-2045(12)70265-6. View

19.

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

20.

Felsberg J, Erkwoh A, Sabel M, Kirsch L, Fimmers R, Blaschke B . Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol. 2004; 14(2):121-30. PMC: 8095961. DOI: 10.1111/j.1750-3639.2004.tb00044.x. View